Home » Newsletters » BioWorld

BioWorld

July 1, 2009

View Archived Issues

Ironed Out at Last: FDA Clears AMAG's Feraheme for Anemia

It was a day late - but AMAG Pharmaceuticals Inc. will hardly end up any dollars short. (BioWorld Today) Read More

Catalyst, Wyeth Partner in $500M Deal for Hemophilia Products

Exclusivity Issue Needlessly Thwarting Biogenerics Debate

Hyperion's Series C Adds $60M for Phase III Trials of HPN-100

Troubled Cell Genesys Signs Merger Deal with BioSante

Clinic Roundup

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...